Ingenuity Pathway Analysis (IPA) software

The Food and Drug Administration is forecasting a future acquisition for Ingenuity Pathway Analysis (IPA) software, a bioinformatics tool used for analyzing and interpreting complex biological data, particularly in research and regulatory evaluations. The procurement is classified under NAICS code 541519, indicating it pertains to other computer-related services, likely including software licensing, support, and associated analytical services. The opportunity is not subject to any specific set-aside classifications and is open to all eligible vendors. The point of contact for program inquiries is the CBER Acquisition Liaison, reachable via cberacquisitions@fda.hhs.gov, while the contracting officer details are still to be determined. The software will support FDA’s mission to evaluate scientific data, potentially in areas such as drug development, safety assessment, or genomic research. Performance location and delivery details have not been specified, and the forecast was posted on May 25, 2026, with no formal solicitation number yet assigned. Stakeholders are encouraged to monitor the official HHS OSDBU portal for updates leading to a formal notice of opportunity.